Stanford University
Showing 1,261-1,270 of 2,212 Results
-
Tracey McLaughlin
Professor of Medicine (Endocrinology)
Current Research and Scholarly InterestsDr. McLaughlin conducts clinical research related to obesity, insulin resistance, diabetes, and cardiovascular disease (CVD). Current studies include: 1) the impact of macronutrient composition on metabolism, DM2 and CVD; 2) comparison of different weight loss diets on metabolism and CVD risk reduction ; 3) role of adipocytes and adipose tissue immune cells in modulating insulin resistance; 4) use of continuous glucose monitoring and multi-omics to define metabolic phenotype and precision diets
-
Bruno Medeiros
Adjunct Clinical Associate Professor, Medicine - Hematology
Current Research and Scholarly InterestsMy clinical activities combine the development of novel therapeutic modalities, translational research activities and epidemiological study of acute leukemia. My special focus is on the development of better, patient tailored therapies for young and elderly patients with acute leukemia.
-
Natalia Medvedeva
Clinical Assistant Professor, Medicine - Infectious Diseases
BioDr Natalia Medvedeva specializes in the treatment of infectious diseases. She has a special interest in antimicrobial stewardship and medical education.
-
Jessica Lee Mega
Affiliate, Medicine - Med/Cardiovascular Medicine
BioJessica L. Mega, MD, MPH is a leader at the intersection of technology, life science, and health care. She is a Cardiologist at Stanford and serves on the Advisory Board for Stanford's Center for Digital Health. She is a Co-Founder of Alphabet's Verily, and she is on the Board of Directors at Boston Scientific and Danaher Corporation, as well as the Board of Advisors for Research!America and the Duke-Margolis Center for Health Policy.
As a faculty member at Harvard Medical School, a Senior Investigator with the TIMI Study Group, and a Cardiologist at Brigham and Women’s Hospital, Dr. Mega led large, international, randomized trials evaluating novel therapies. She also directed the TIMI Study Group’s Genomics Program, demonstrating and testing the role of CYP2C19 genetic variants on antiplatelet medications, a key pharmacogenetic finding. She has published manuscripts in the New England Journal of Medicine, Lancet, and JAMA. She served as an Advisor for the California Governor’s Precision Medicine Initiative.
Dr. Mega is a graduate of Stanford University, Yale University School of Medicine, and Harvard School of Public Health. She completed Internal Medicine Residency at Brigham and Women’s Hospital and Cardiovascular Fellowship at Massachusetts General Hospital. She is board certified in Internal Medicine and Cardiology. She has won the Laennec Society, Samuel A. Levine, and Douglas P. Zipes Awards, and she is a Fellow of the American Heart Association (AHA) and the American College of Cardiology (ACC).